THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC

The Global Alliance for TB Drug Development Inc. specializes in pioneering research and development of novel therapeutics targeting tuberculosis, with a focus on proteostasis modulation as a mechanistic strategy for disrupting Mycobacterium tuberculosis viability. Their technical expertise lies in molecular pharmacology, target validation, and small-molecule drug discovery within the life sciences domain, particularly in identifying and optimizing compounds that restore cellular protein homeostasis to combat drug-resistant strains. The organization distinguishes itself through its mission-driven approach to infectious disease innovation, leveraging cutting-edge biochemical and cellular assays to advance preclinical candidates toward clinical translation. Their work bridges fundamental biological insights with translational drug development, emphasizing unmet needs in global health. The contractor has demonstrated direct engagement with the Department of Health and Human Services, delivering high-impact R&D initiatives aligned with public health priorities in infectious disease control. Their relationship with HHS reflects a focused partnership in advancing next-generation tuberculosis therapeutics, typically through targeted grants supporting early-stage discovery and mechanistic validation of novel targets. Their primary industry focus is on Research and Development in the Life Sciences, specifically the design and evaluation of non-traditional antimicrobial modalities that exploit host-directed pathways rather than direct bacterial targeting. This positions them at the intersection of infectious disease biology and precision pharmacology, serving a niche but critical segment of the global health R&D market. As a non-profit entity structured under 8H, The Global Alliance for TB Drug Development Inc. operates from New York, NY, with a mission-driven governance model centered on public health outcomes. While no formal government certifications are held, their work is recognized for its alignment with federal health security priorities, and they maintain a specialized footprint in the global tuberculosis therapeutic development ecosystem.